Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials

被引：0
|
作者：
Walmsley, S. [1 ]
Squires, K. [2 ]
Martin, E. [2 ]
Xu, Z. J. [2 ]
Hwang, C. [2 ]
Sklar, P. [2 ]
Sordet, F. [2 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE3/9
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [21] Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data
    W. Joseph Herring
    Kathryn M. Connor
    Ellen Snyder
    Duane B. Snavely
    Ying Zhang
    Jill Hutzelmann
    Deborah Matzura-Wolfe
    Ruth M. Benca
    Andrew D. Krystal
    James K. Walsh
    Christopher Lines
    Thomas Roth
    David Michelson
    Psychopharmacology, 2017, 234 : 1703 - 1711
  • [22] Pooled Safety Analysis of Enobosarm from Phase 2 and Phase 3 Placebo-Controlled Clinical Trials
    Crawford, Jeffrey
    Dobs, Adrian S.
    Evans, William J.
    Prado, Carla
    Rodriguez, Domingo
    Shalev, Itay
    Barnette, K. Gary
    Steiner, Mitchell
    DIABETES, 2024, 73
  • [23] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH REVEFENACIN FOR NEBULIZATION IN WOMEN VS MEN WITH MODERATE TO VERY SEVERE COPD: SUBGROUP ANALYSES FROM PHASE 3 CLINICAL TRIALS
    Ferguson, Gary
    Feldman, Gregory
    Pudi, Krishna
    Lombardi, David
    Ohar, Jill
    Schneider, Roslyn
    CHEST, 2021, 160 (04) : 1777A - 1779A
  • [24] Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
    Fogacci, Federica
    Norata, Giuseppe Danilo
    Toth, Peter P.
    Arca, Marcello
    Cicero, Arrigo F. G.
    CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (05)
  • [25] Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
    Federica Fogacci
    Giuseppe Danilo Norata
    Peter P. Toth
    Marcello Arca
    Arrigo F. G. Cicero
    Current Atherosclerosis Reports, 2020, 22
  • [26] Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C
    Lacy, B. E.
    Lembo, A. J.
    MacDougall, J. E.
    Shiff, S. J.
    Kurtz, C. B.
    Currie, M. G.
    Johnston, J. M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (03): : 326 - 333
  • [27] Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
    Simon, James A.
    Altomare, Corrado
    Cort, Susannah
    Jiang, Wei
    Pinkerton, JoAnn V.
    JOURNAL OF WOMENS HEALTH, 2018, 27 (01) : 14 - 23
  • [28] Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials
    Gossec, Laure
    Balanescu, Andra
    D'Agostino, Maria Antonietta
    Ogdie, Alexis
    Sewerin, Philipp
    Deng, Yu
    Shi, Linyu
    Sugimoto, Yoshiyuki
    Zhong, Sheng
    Xing, Yunzhao
    Lippe, Ralph
    Kishimoto, Mitsumasa
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4752 - 4756
  • [29] Secukinumab shows efficacy in subjects regardless of previous exposure to biologic therapy: A pooled subanalysis from four phase 3 clinical trials in psoriasis
    Griffiths, Christopher
    Papp, Kim
    Zaldivar, Enrique Rivas
    Nakagawa, Hidemi
    Gong, Yankun
    Fox, Todd
    Papavassilis, Charis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB251 - AB251
  • [30] Differences in COPD Exacerbation Risk Between Women and Men Analysis From the UK Clinical Practice Research Datalink Data
    Stolz, Daiana
    Kostikas, Konstantinos
    Loefroth, Emil
    Fogel, Robert
    Gutzwiller, Florian S.
    Conti, Valentino
    Cao, Hui
    Clemens, Andreas
    CHEST, 2019, 156 (04) : 674 - 684
12345